Effects of auranofin on leukotriene production and leukotriene stimulated neutrophil function.
Arachidonic acid is metabolized in neutrophils by lipoxygenase to leukotrienes, which are suggested to play a central role in inflammation. The antirheumatic drug auranofin (4 micrograms/ml) was found not to inhibit neutrophil production of the lipoxygenase products 5-HETE-, 15-HETE and LTB4, in vitro when stimulated with the calcium ionophore A23187. Auranofin, however, modulated neutrophil aggregation, enzyme release and chemotaxis induced by LTB4. The results suggest that auranofin may exert some of its antirheumatic effects through affecting neutrophil responses to leukotrienes.
D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives* / Q000494:pharmacology; D002449:Cell Aggregation; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D005966:Glucuronidase / Q000378:metabolism; D006046:Gold / Q000031:analogs & derivatives*; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000096:biosynthesis; D007975:Leukotriene B4 / Q000096:biosynthesis / Q000494:pharmacology*; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects*
D000893:Anti-Inflammatory Agents; D006893:Hydroxyeicosatetraenoic Acids; D007975:Leukotriene B4; D006051:Aurothioglucose; D001310:Auranofin; C022022:5-hydroxy-6,8,11,14-eicosatetraenoic acid; D009240:N-Formylmethionine Leucyl-Phenylalanine; C025984:15-hydroxy-5,8,11,13-eicosatetraenoic acid; D006046:Gold; D005966:Glucuronidase